ArticleJournal of interventional medicine2022
Thermal ablation for papillary thyroid microcarcinoma: Some clarity amid controversies.
Article in Journal of interventional medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 2 citations in OpenAlex.
- The clinical utility of thermal ablation procedures in thyroid nodules: Latin American Thyroid Society (LATS) surgical affairs committee expert opinion. Part 2.Archives of endocrinology and metabolism · 2025Review
- Complications of ultrasound-guided thermal ablation of thyroid nodules and associated risk factors: an experience from 9667 cases.European radiology · 2025Article
- Incomplete ablation of thyroid cancer: Achilles' Heel?BMC endocrine disorders · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing incidence of papillary thyroid microcarcinoma (PTMC) has become a global challenge. Because of its indolent nature, active surveillance (AS) has been proposed as a treatment option in selected PTMC patients to prevent surgery-related complications. However, only a few patients with PTMC receive the AS approach because of the serious psychological burden following the "cancer" diagnosis and the uncertainty of the timing for metastatic dissemination. Ultrasound (US)-guided thermal ablation can bridge the gap in the treatment options of PTMC patients who wish for a minimally invasive management approach. However, it has acquired only marginal attention from the thyroid guideline societies because of concerns regarding incomplete elimination. The recently published guidelines from the European Thyroid Association-Cardiovascular and Interventional Radiological Society of Europe and the American Head Neck Society Endocrine Section -initiated global consensus provide the most definitive evidence and essential foundational experience to address the long-term controversy over US-guided thermal ablation for low-risk PTMC patient management and facilitate the responsible global dissemination of minimally invasive strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.